Trial Profile
IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Prostate cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms IMPACT
- 21 Jun 2023 Planned End Date changed from 1 May 2023 to 1 Dec 2024.
- 01 Aug 2022 Treatment arms increased from 2 to 3
- 01 Aug 2022 Planned number of patients changed from 40 to 65.